Supplementary material

Supplementary table 1. Duration of TKI response before treatment interruption/discontinuation per sub-characteristic (N=69; whole population analysis)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Patients characteristics** | | **n** | **Duration (weeks)** | | |
| **mean** | **median** | **range** |
| Gender | male | 36 | 113.6 | 30 | 0–603 |
| female | 33 | 110.4 | 37 | 0–615 |
| Sokal risk score | low | 18 | 141.6 | 68 | 0–539 |
| intermediate | 25 | 64.4 | 21 | 0–615 |
| high | 1 | 38.0 | 38 | 38–38 |
| not available | 25 | 141.4 | 79 | 0–603 |
| Age at latest interruption/discontinuation\* | ≤64 years | 33 | 116.3 | 43 | 0–615 |
| >64 years | 36 | 108.2 | 25 | 0–603 |
| ≤61 years | 30 | 123.1 | 53 | 0–615 |
| >61 years | 39 | 103.6 | 27 | 0–603 |
| Phase of CML | chronic | 69 | 112.0 | 37 | 0–615 |
| Line of TKI treatment | 1st | 28 | 128.9 | 42 | 0–539 |
| 2nd | 25 | 111.6 | 27 | 0–615 |
| 3rd | 4 | 87.1 | 91 | 5–162 |
| 4th | 4 | 169.5 | 38 | 0–603 |
| 5th | 5 | 59.7 | 21 | 0–249 |
| 6th | 3 | 2.4 | 2 | 1–4 |
| TKI received prior to interruption/discontinuation | imatinib | 34 | 167.8 | 68 | 0–615 |
| nilotinib | 12 | 71.5 | 32 | 1–249 |
| dasatinib | 20 | 58.3 | 27 | 0–399 |
| ponatinib | 3 | 0.6 | 0 | 0–2 |
| Time between CML diagnosis and treatment interruption/discontinuation\* | ≤363 weeks | 35 | 56.0 | 37 | 0–263 |
| >363 weeks | 34 | 169.8 | 34 | 0–615 |
| ≤426 weeks | 39 | 64.2 | 37 | 0–399 |
| >426 weeks | 30 | 174.3 | 34 | 0–615 |
| Duration of TKI treatment that was interrupted/discontinued\* | ≤169 weeks | 35 | 41.4 | 5 | 0–424 |
| >169 weeks | 34 | 184.8 | 129 | 0–615 |
| ≤238 weeks | 42 | 55.5 | 18 | 0–424 |
| >238 weeks | 27 | 200.1 | 117 | 0–615 |
| Response at the time of TKI treatment interruption/discontinuation | CHR | 15 | 9.4 | 2 | 0–64 |
| CCyR | 2 | 126.6 | 127 | 4–249 |
| MMR | 16 | 125.4 | 85 | 0–394 |
| MR4 | 11 | 153.2 | 27 | 0–615 |
| MR4.5 or deeper | 25 | 145.9 | 63 | 0–603 |

N, total number of treatment interruptions/discontinuations; n, number in each (sub)category.

Note: \*Subcategories were defined by using calculated means and medians for the overall population: 61 and 64 years, respectively for age; 426 and 363 weeks, respectively for time between CML diagnosis and treatment interruption/discontinuation; and 238 and 169 weeks, respectively, for the duration of the TKI treatment which was interrupted/discontinued.

Supplementary table 2. Reason for TKI treatment interruption or discontinuation per sub-characteristic (N=69; whole population analysis)

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Patients characteristics** | | **TFR attempt** | | **Wish to conceive** | | **Spontaneous request of patient** | | **Due to side effects**  **or intolerance** | | **Other** | |
| **n** | **%** | **n** | **%** | **n** | **%** | **n** | **%** | **n** | **%** |
| Overall | | 6 | 9 | 6 | 9 | 2 | 3 | 46 | 67 | 9 | 13 |
| Gender | male | 4 | 6 | 3 | 4 | 2 | 3 | 21 | 30 | 6 | 9 |
| female | 2 | 3 | 3 | 4 | 0 | - | 25 | 36 | 3 | 4 |
| Sokal risk score | low | 0 | - | 3 | 4 | 0 | - | 12 | 17 | 3 | 4 |
| intermediate | 1 | 1 | 1 | 1 | 1 | 1 | 17 | 25 | 5 | 7 |
| high | 0 | - | 0 | - | 0 | - | 1 | 1 | 0 | - |
| not available | 5 | 7 | 2 | 3 | 1 | 1 | 16 | 23 | 1 | 1 |
| Age at latest interruption/discontinuation\* | ≤64 years | 2 | 3 | 6 | 9 | 2 | 3 | 19 | 28 | 4 | 6 |
| >64 years | 4 | 6 | 0 | - | 0 | - | 27 | 39 | 5 | 7 |
| ≤61 years | 1 | 1 | 6 | 9 | 2 | 3 | 17 | 25 | 4 | 6 |
| >61 years | 5 | 7 | 0 | - | 0 | - | 29 | 42 | 5 | 7 |
| Phase of CML | chronic | 6 | 9 | 6 | 9 | 2 | 3 | 46 | 67 | 9 | 13 |
| Line of TKI treatment | 1st | 2 | 3 | 3 | 4 | 1 | 1 | 17 | 25 | 5 | 7 |
| 2nd | 4 | 6 | 2 | 3 | 1 | 1 | 15 | 22 | 3 | 4 |
| 3rd | 0 | - | 1 | 1 | 0 | - | 3 | 4 | 0 | - |
| 4th | 0 | - | 0 | - | 0 | - | 4 | 6 | 0 | - |
| 5th | 0 | - | 0 | - | 0 | - | 4 | 6 | 1 | 1 |
| 6th | 0 | - | 0 | - | 0 | - | 3 | 4 | 0 | - |
| TKI received prior to interruption/discontinuation | imatinib | 5 | 7 | 4 | 6 | 1 | 1 | 20 | 29 | 4 | 6 |
| nilotinib | 1 | 1 | 2 | 3 | 1 | 1 | 6 | 9 | 2 | 3 |
| dasatinib | 0 | - | 0 | - | 0 | - | 17 | 25 | 3 | 4 |
| ponatinib | 0 | - | 0 | - | 0 | - | 3 | 4 | 0 | - |
| Time between CML diagnosis and treatment interruption/ discontinuation\* | ≤363 weeks | 1 | 1 | 2 | 3 | 2 | 3 | 23 | 33 | 7 | 10 |
| >363 weeks | 5 | 7 | 4 | 6 | 0 | - | 23 | 33 | 2 | 3 |
| ≤426 weeks | 1 | 1 | 2 | 3 | 2 | 3 | 26 | 38 | 8 | 12 |
| >426 weeks | 5 | 7 | 4 | 6 | 0 | - | 20 | 29 | 1 | 1 |
| Duration of TKI treatment that was interrupted/discontinued\* | ≤169 weeks | 1 | 1 | 1 | 1 | 0 | - | 27 | 39 | 6 | 9 |
| >169 weeks | 5 | 7 | 5 | 7 | 2 | 3 | 19 | 28 | 3 | 4 |
| ≤238 weeks | 1 | 1 | 1 | 1 | 1 | 1 | 31 | 45 | 8 | 12 |
| >238 weeks | 5 | 7 | 5 | 7 | 1 | 1 | 15 | 22 | 1 | 1 |
| Response at the time of TKI treatment interruption/discontinuation | CHR | 0 | - | 0 | - | 0 | - | 13 | 19 | 2 | 3 |
| CCyR | 0 | - | 0 | - | 0 | - | 2 | 3 | 0 | - |
| MMR | 0 | - | 4 | 6 | 1 | 1 | 7 | 10 | 4 | 6 |
| MR4 | 2 | 3 | 1 | 1 | 0 | - | 7 | 10 | 1 | 1 |
| MR4.5 or deeper | 4 | 6 | 1 | 1 | 1 | 1 | 17 | 25 | 2 | 3 |

N, total number of treatment interruptions/discontinuations; n (%), number (percentage) in each (sub)category.

Note: \*Subcategories were defined by using calculated means and medians for the overall population: 61 and 64 years, respectively for age; 426 and 363 weeks, respectively for time between CML diagnosis and treatment interruption/discontinuation; and 238 and 169 weeks, respectively, for the duration of the TKI treatment which was interrupted/discontinued.